Protagonist Therapeutics (PTGX) Cash & Equivalents (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Cash & Equivalents of $193.7 million for Q1 2026, up 50.88% sequentially from $128.4 million in Q4 2025, and up 38.71% YoY from $139.7 million in Q1 2025.
Protagonist Therapeutics (PTGX) Cash & Equivalents (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Cash & Equivalents for 12 years, with the latest figure at $193.7 million in Q1 2026.
- Quarterly Cash & Equivalents rose 38.71% year-over-year to $193.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.7 million (up 38.71% YoY) and the FY2025 annual result came in at $128.4 million, up 32.02% from the prior year.
- Cash & Equivalents rose to $193.7 million in Q1 2026 per PTGX's latest filing, from $128.4 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $355.6 million in Q2 2024 and troughed at $97.2 million in Q4 2024.
- A 5-year average of $163.4 million and a median of $139.7 million in 2025 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 95.77% in 2023, then sank 52.61% in 2025.
- Over 5 years, Cash & Equivalents stood at $125.7 million in 2022, then surged by 48.5% to $186.7 million in 2023, then slumped by 47.92% to $97.2 million in 2024, then jumped by 32.02% to $128.4 million in 2025, then surged by 50.88% to $193.7 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $193.7 million, $128.4 million, and $113.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 420.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 420.08 Mn |
| Mar 31, 2026 | 193.71 Mn |
| Dec 31, 2025 | 128.39 Mn |
| Sep 30, 2025 | 113.71 Mn |
| Jun 30, 2025 | 168.54 Mn |
| Mar 31, 2025 | 139.65 Mn |
| Dec 31, 2024 | 97.25 Mn |
| Sep 30, 2024 | 131.12 Mn |
| Jun 30, 2024 | 355.64 Mn |
| Mar 31, 2024 | 172.57 Mn |
| Dec 31, 2023 | 186.73 Mn |
| Sep 30, 2023 | 230.53 Mn |
| Jun 30, 2023 | 235.38 Mn |
| Mar 31, 2023 | 127.69 Mn |
| Dec 31, 2022 | 125.74 Mn |
| Sep 30, 2022 | 152.82 Mn |
| Jun 30, 2022 | 120.24 Mn |
| Mar 31, 2022 | 98.48 Mn |
| Dec 31, 2021 | 123.67 Mn |
| Sep 30, 2021 | 120.54 Mn |